GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has already received a voucher to speed up its review under a new FDA pilot program.
The post GSK Eyes FDA Filing After Immunotherapy Succeeds in Key Rectal Cancer Study appeared first on MedCity News.
